Asher Biotherapeutics (Asher Bio) is a privately held, clinical-stage biotechnology company founded in 2019 and headquartered at 650 Gateway Blvd. in South San Francisco, California. The company develops cis-targeted immunotherapies — engineered biologics that simultaneously engage an immunomodulatory receptor and a cell-type-specific target on the same immune cell, so a cytokine is only activated on the intended cell population rather than acting indiscriminately across immune subsets. Its lead candidate, etakafusp alfa (AB248), is a cis-targeted IL-2 directed at CD8+ effector T cells and is in Phase 1a/1b clinical development in cancer, alongside earlier-stage programs AB821 and AB359 and a cis-targeted cytokine augmentation program for cell therapies. Asher Bio is a therapeutics developer, not a software or platform company: it publishes no developer program, public API, SDK, or machine-readable interface.
Asher Biotherapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immunotherapy, Oncology, and Therapeutics.
Asher Biotherapeutics’ developer surface includes engineering blog and 10 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Show this score on your site.
It updates itself when the score changes. Paste this where you link to your API docs:
<a href="https://apis.io/providers/asher-biotherapeutics/"><img src="https://apis.io/badge/asher-biotherapeutics/card.svg" alt="Asher Biotherapeutics on APIs.io — Kin Score by API Evangelist"></a>
Other styles, a README pill and a shields.io endpoint are on the badge page.
Raise your score.
Agent readiness — checks not met, largest first (exact, from this profile):
Machine-Readable Auth+10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
Idempotency+9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
Stable Error Semantics+8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes
13 more unmet checks in the Agent Readiness table above.
Kin Score — facets with the most composite points still available (weight × headroom):
aid: asher-biotherapeutics
name: Asher Biotherapeutics
description: 'Asher Biotherapeutics (Asher Bio) is a privately held, clinical-stage biotechnology company founded in 2019
and headquartered at 650 Gateway Blvd. in South San Francisco, California. The company develops cis-targeted immunotherapies
— engineered biologics that simultaneously engage an immunomodulatory receptor and a cell-type-specific target on the same
immune cell, so a cytokine is only activated on the intended cell population rather than acting indiscriminately across
immune subsets. Its lead candidate, etakafusp alfa (AB248), is a cis-targeted IL-2 directed at CD8+ effector T cells and
is in Phase 1a/1b clinical development in cancer, alongside earlier-stage programs AB821 and AB359 and a cis-targeted cytokine
augmentation program for cell therapies. Asher Bio is a therapeutics developer, not a software or platform company: it publishes
no developer program, public API, SDK, or machine-readable interface.'
deliveryModel:
model: saas
open_source: false
commercial: true
callable_host: false
label: Hosted service · you call their endpoint
confidence: medium
source:
- pricing
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
probe_state: none
source:
- security
generated: '2026-11-06'
method: derived
image: https://asherbio.com/wp-content/uploads/2021/03/home-page-card-Asher-032221.jpg
url: https://raw.githubusercontent.com/api-evangelist/asher-biotherapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-10-06'
tags:
- Company
- Biotechnology
- Immunotherapy
- Oncology
- Therapeutics
- Clinical Stage
- Life Sciences
- Cytokines
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- url: https://asherbio.com/feed/
type: BlogRSS
- type: Website
url: https://asherbio.com/
- type: PrivacyPolicy
url: https://asherbio.com/privacy-policy/
- type: TermsOfService
url: https://asherbio.com/terms-of-use/
- type: Blog
url: https://asherbio.com/news/press-releases/
- type: BlogRSS
url: https://asherbio.com/news/press-releases/feed/
- type: Contact
url: https://asherbio.com/contact-us/
- type: Careers
url: https://asherbio.com/careers/
- type: About
url: https://asherbio.com/about-us/
- type: SecondaryMarket
url: https://forgeglobal.com/asher-biotherapeutics_stock/
- type: DomainSecurity
url: security/asher-biotherapeutics-domain-security.yml
x-enrichment:
date: '2026-08-06'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Asher Bio is a clinical-stage biologics developer whose product is a drug, not software — its entire WordPress site
is four sections (platform, pipeline, news, careers) with no developer, API, or docs path; asherbio.com/api, /developers
and /docs all return the site's 404 page.
evidence:
- url: https://asherbio.com/api
status: 404
- url: https://asherbio.com/developers
status: 404
- url: https://asherbio.com/openapi.json
status: 404
- url: https://asherbio.com/.well-known/agent-card.json
status: 404
- url: https://asherbio.com/llms.txt
status: 404
- url: https://asherbio.com/sitemap.xml
status: 200
checked: '2026-08-06'
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.